title: Radiotherapy-induced emesis. An overview.
abstract: BACKGROUND
  A significant number of patients receiving radiotherapy experience the distressing side effects of emesis and nausea. These symptoms are some of the most distressing problems for the patients influencing their quality of life.
  
  
  METHODS
  International study results concerning radiotherapy-induced emesis are demonstrated. A German multicenter questionnaire examining the strategies to prevent or to treat radiotherapy-induced nausea and emesis is presented. An international analysis concerning incidence of emesis and nausea in fractionated radiotherapy patients is discussed. Finally the consensus of the consensus conference on antiemetic therapy from the Perugia International Cancer Conference V is introduced.
  
  
  RESULTS
  Untreated emesis can lead to complications like electrolyte disorders, dehydration, metabolic disturbances and nutrition problems with weight loss. Prophylactic antiemetics are often given to patients receiving single high-dose radiotherapy to the abdomen. A survey has revealed that antiemetic prophylaxis is not routinely offered to the patients receiving fractionated radiotherapy. However, there is a need for an effective treatment of emesis for use in this group of patients, too. In 20% of patients nausea and emesis can cause a treatment interruption because of an inadequate control of symptoms. Like in chemotherapy strategies there exists high, moderate, and low emetogenic treatment regimens in radiotherapy as well. The most emetogenic potential has the total body irradiation followed by radiotherapy to the abdomen. Radiotherapy induced emesis can be treated effectively with conventional antiemetics up to 50%.
  
  
  CONCLUSIONS
  Studies with total body irradiation, fractionated treatment and high-dose single exposures have clearly demonstrated the value of 5-HT3-receptor antagonist antiemetics. There is a response between 60 and 97%. There is no difference in the efficacy of the different 5-HT3-antagonists. High-risk patients should be prophylactic treated with 5-HT3-antagonists. The additional administration of glucocorticoids and benzodiazepins can optimize the response.
authors.affiliation: Department Radiotherapy, Campus Charité-Mitte, Humboldt-University Berlin. petra.feyer.@charite.de
authors.forename: P
authors.initials: P
authors.lastname: Feyer
authors.forename: J S
authors.initials: JS
authors.lastname: Zimmermann
authors.forename: O J
authors.initials: OJ
authors.lastname: Titlbach
authors.forename: A
authors.initials: A
authors.lastname: Buchali
authors.forename: M
authors.initials: M
authors.lastname: Hinkelbein
authors.forename: V
authors.initials: V
authors.lastname: Budach
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use; D019583:Dose Fractionation, Radiation; D006801:Humans; D009325:Nausea / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control; D011878:Radiotherapy / Q000009:adverse effects*; D014839:Vomiting / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control; D014883:Water-Electrolyte Imbalance / Q000209:etiology
chemical_list: D000932:Antiemetics